Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database

Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and mechanistic target of rapamycin kinase (mTOR) inhibitors are common first-line (1  L) treatments for metastatic renal cell carcinoma (mRCC). D...

Source: BMC Cancer - June 7, 2019 Category: Cancer & Oncology Authors: Sumanta Pal, Jun Gong, Shivani K. Mhatre, Shih-Wen Lin, Andy Surinach, Sarika Ogale, Rini Vohra, Herschel Wallen and Daniel George Tags: Research article Source Type: research